1
Home
Companies

OncoCyte

#9333

Rank

$91.52M

Marketcap

US United States

Country

OncoCyte
Leadership team

Dr. Douglas T. Ross M.D., Ph.D. (Chief Science Officer)

Mr. Joshua Riggs (Interim Chief Exec. Officer)

Mr. Ronald A. Andrews Jr. (Consultant)

Products/ Services
Biotechnology, Health Care, Hospital, Medical Device
Number of Employees
100 - 500
Headquarters
Irvine, California, United States
Established
2009
Company Registration
SEC CIK number: 0001642380
Revenue
5M - 20M
Traded as
OCX
Social Media
URL
https://oncocyte.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
History

OncoCyte was founded in 2007 by the veteran biotechnology team of Dr. Dennis A. Augustine and Nan H. Xue. OncoCyte has been founded with a mission to fight cancer and improve patient outcomes. Through its proprietary platform and innovative technologies, OncoCyte leverages its deep expertise in cell biology, genetics and biochemistry, to develop and commercialize non-invasive tests.

Mission
Our mission is to utilize the power of science and technology to fight cancer and improve patient outcomes.
Vision
Our vision is to revolutionize the early detection, diagnosis, and prognosis of cancer, ultimately resulting in improved outcomes that enable patients and their families to live healthier, happier lives.
Key Team

Ms. Gisela A. Paulsen (COO & Pres)

Mr. James Liu (Controller & Principal Accounting Officer)

Mr. Anish John (Chief Financial Officer)

Dr. Ekkehard Schutz M.D., Ph.D. (Chief Technology Officer)

Mr. Robert S. Seitz (Head of Immune Oncology)

Mr. William Annett (Advisor)

Dr. Michael D. West Ph.D. (Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.)

Recognition and Awards
OncoCyte has won numerous awards for its innovative technologies and its commitment to advancing cancer diagnostics. Awards include “Best in Show” from the NCI Innovation Showcase, winner of “Best Early Stage Company from the NCI SBIR initiative, and winner of numerous awards from the Bio Services EU Innovation Hub.
References

https://en.wikipedia.org/wiki/Oncocyte

https://in.investing.com/equities/oncocyte-corp

https://finance.yahoo.com/quote/OCX/profile?p=OCX

https://www.crunchbase.com/organization/oncocyte

https://companiesmarketcap.com/

https://oncocyte.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

OncoCyte
Leadership team

Dr. Douglas T. Ross M.D., Ph.D. (Chief Science Officer)

Mr. Joshua Riggs (Interim Chief Exec. Officer)

Mr. Ronald A. Andrews Jr. (Consultant)

Products/ Services
Biotechnology, Health Care, Hospital, Medical Device
Number of Employees
100 - 500
Headquarters
Irvine, California, United States
Established
2009
Company Registration
SEC CIK number: 0001642380
Revenue
5M - 20M
Traded as
OCX
Social Media
URL
https://oncocyte.com